MedPath

BioXmark, bladder safety and performance trial

Recruiting
Conditions
Muscle invasive bladder cancer
Registration Number
NL-OMON23138
Lead Sponsor
Amsterdam UMC location AMC
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
Not specified
Target Recruitment
20
Inclusion Criteria

•Patients with histologically proven primary bladder cancer

•Referred for bladder conserving (chemo-)radiotherapy

Exclusion Criteria

•Any contraindication for an cystoscopic procedure

•Pregnant women

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of BioXmark liquid fiducial markers which are visible and remain in a stable position from the CT acquisition for RT planning to last CBCT <br /><br>Number of adverse events potentially associated with application of BioXmark liquid fiducial markers
Secondary Outcome Measures
NameTimeMethod
•Percentage of markers lost from injection to the CT acquisition for RT planning<br /><br>•Percentage of patients in which markers can be used for target delineation<br /><br>•Percentage of patients in which markers can be used for patient set-up
© Copyright 2025. All Rights Reserved by MedPath